American Vanguard (AVD) 10-Q 6 Aug 18 2018 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2018	Jul. 30, 2018
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2018
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q2
Trading Symbol	AVD
Entity Registrant Name	AMERICAN VANGUARD CORP
Entity Central Index Key	5,981
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		30,324,493

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Income Statement [Abstract]
Net sales	$ 107,046	$ 77,905	$ 211,154	$ 148,578
Cost of sales	63,749	43,570	126,806	84,159
Gross profit	43,297	34,335	84,348	64,419
Operating expenses	34,718	27,654	68,418	52,605
Operating income	8,579	6,681	15,930	11,814
Interest expense, net	966	400	1,803	698
Income before provision for income taxes and loss on equity method investments	7,613	6,281	14,127	11,116
Income tax expense	1,748	1,681	3,440	3,061
Income before loss on equity method investments	5,865	4,600	10,687	8,055
Loss from equity method investments	301	69	518	111
Net income	5,564	4,531	10,169	7,944
Net loss (income) attributable to non-controlling interest	35	(227)	85	(188)
Net income attributable to American Vanguard	$ 5,599	$ 4,304	$ 10,254	$ 7,756
Earnings per common share—basic	$ 0.19	$ 0.15	$ 0.35	$ 0.27
Earnings per common share—assuming dilution	$ 0.19	$ 0.15	$ 0.34	$ 0.26
Weighted average shares outstanding—basic	29,330	29,050	29,309	28,999
Weighted average shares outstanding—assuming dilution	30,190	29,605	30,113	29,561

CONDENSED CONSOLIDATED STATEME3

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Statement Of Income And Comprehensive Income [Abstract]
Net income	$ 5,564	$ 4,531	$ 10,169	$ 7,944
Comprehensive income:
Foreign currency translation adjustment	(898)	280	(226)	1,037
Comprehensive income	4,666	4,811	9,943	8,981
Net loss (income) attributable to non-controlling interest	35	(227)	85	(188)
Comprehensive income attributable to American Vanguard	$ 4,701	$ 4,584	$ 10,028	$ 8,793

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 7,099	$ 11,337
Receivables:
Trade, net of allowance for doubtful accounts of $259 and $46, respectively	94,933	102,534
Other	12,011	7,071
Total receivables, net	106,944	109,605
Inventories	163,180	123,124
Prepaid expenses	11,290	10,817
Total current assets	288,513	254,883
Property, plant and equipment, net	48,399	49,321
Intangible assets, net of applicable amortization	177,512	180,950
Goodwill	21,837	22,184
Other assets	25,753	28,254
Total assets	562,014	535,592
Current liabilities:
Current installments of other liabilities	3,534	5,395
Accounts payable	64,842	53,748
Deferred revenue	7,320	14,574
Accrued Program costs	54,093	39,054
Accrued expenses and other payables	9,786	12,061
Income taxes payable	1,085	1,370
Total current liabilities	140,660	126,202
Long-term debt, net of deferred loan fees	74,258	77,486
Other liabilities, excluding current installments	9,641	10,306
Deferred income tax liabilities	17,224	16,284
Total liabilities	241,783	230,278
Commitments and contingent liabilities
Stockholders' equity:
Preferred stock, $.10 par value per share; authorized 400,000 shares; none issued
Common stock, $.10 par value per share; authorized 40,000,000 shares; issued 32,743,504 shares at June 30, 2018 and 32,241,866 shares at December 31, 2017	3,275	3,225
Additional paid-in capital	79,721	75,658
Accumulated other comprehensive loss	(4,733)	(4,507)
Retained earnings	250,068	238,953
Total stockholders' equity including treasury stock	328,331	313,329
Less treasury stock at cost, 2,450,634 shares at June 30, 2018 and December 31, 2017	(8,269)	(8,269)
American Vanguard Corporation stockholders’ equity	320,062	305,060
Non-controlling interest	169	254
Total stockholders’ equity	320,231	305,314
Total liabilities and stockholders' equity	$ 562,014	$ 535,592

CONDENSED CONSOLIDATED BALANCE5

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Statement Of Financial Position [Abstract]
Allowance for doubtful accounts	$ 259	$ 46
Preferred stock, par value per share	$ 0.10	$ 0.10
Preferred stock, shares authorized	400,000	400,000
Preferred stock, shares issued	0	0
Common stock, par value per share	$ 0.10	$ 0.10
Common stock, shares authorized	40,000,000	40,000,000
Common stock, shares issued	32,743,504	32,241,866
Treasury stock, shares	2,450,634	2,450,634

CONDENSED CONSOLIDATED STATEME6

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Loss	Retained Earnings	Treasury Stock	AVD Total	Non- Controlling Interest
Balance at Dec. 31, 2017	$ 305,314	$ 3,225	$ 75,658	$ (4,507)	$ 238,953	$ (8,269)	$ 305,060	$ 254
Balance (in shares) at Dec. 31, 2017	32,241,866	32,241,866				2,450,634
Adjustment to recognize new standard on taxes on foreign asset transfers	$ (180)				(180)		(180)
Common stock issued under ESPP	299	$ 1	298				299
Common stock issued under ESPP, Shares		17,078
Cash dividends on common stock ($0.02 per share)	(586)				(586)		(586)
Foreign currency translation adjustment, net	672			672			672
Stock based compensation	1,309		1,309				1,309
Stock options exercised; grants and vesting of restricted stock units	511	$ 41	470				511
Stock options exercised; grants and vesting of restricted stock units, Shares		409,979
Net income	4,605				4,655		4,655	(50)
Balance at Mar. 31, 2018	314,158	$ 3,267	77,735	(3,835)	245,056	$ (8,269)	313,954	204
Balance (in shares) at Mar. 31, 2018		32,668,923				2,450,634
Balance at Dec. 31, 2017	$ 305,314	$ 3,225	75,658	(4,507)	238,953	$ (8,269)	305,060	254
Balance (in shares) at Dec. 31, 2017	32,241,866	32,241,866				2,450,634
Foreign currency translation adjustment, net	$ (226)
Net income	10,169
Balance at Jun. 30, 2018	$ 320,231	$ 3,275	79,721	(4,733)	250,068	$ (8,269)	320,062	169
Balance (in shares) at Jun. 30, 2018	32,743,504	32,743,504				2,450,634
Adjustment to recognize new revenue recognition standard, net of tax	$ 2,214				2,214		2,214
Balance at Mar. 31, 2018	314,158	$ 3,267	77,735	(3,835)	245,056	$ (8,269)	313,954	204
Balance (in shares) at Mar. 31, 2018		32,668,923				2,450,634
Cash dividends on common stock ($0.02 per share)	(587)				(587)		(587)
Foreign currency translation adjustment, net	(898)			(898)			(898)
Stock based compensation	1,469		1,469				1,469
Stock options exercised; grants and vesting of restricted stock units	525	$ 8	517				525
Stock options exercised; grants and vesting of restricted stock units, Shares		74,581
Net income	5,564				5,599		5,599	(35)
Balance at Jun. 30, 2018	$ 320,231	$ 3,275	$ 79,721	$ (4,733)	$ 250,068	$ (8,269)	$ 320,062	$ 169
Balance (in shares) at Jun. 30, 2018	32,743,504	32,743,504				2,450,634

CONDENSED CONSOLIDATED STATEME7

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (Parenthetical) - $ / shares	3 Months Ended
	Jun. 30, 2018	Mar. 31, 2018
Statement Of Stockholders Equity [Abstract]
Cash dividends on common stock, per share	$ 0.02	$ 0.02

CONDENSED CONSOLIDATED STATEME8

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Cash flows from operating activities:
Net income	$ 10,169	$ 7,944
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization of fixed and intangible assets	9,516	8,094
Amortization of other long term assets	2,313	2,777
Amortization of discounted liabilities	202	13
Stock-based compensation	2,778	2,322
Change in deferred income taxes	(26)	7
Loss from equity method investments	518	111
Changes in assets and liabilities associated with operations:
Decrease in net receivables	5,478	20,749
Increase in inventories	(40,194)	(5,506)
Increase in prepaid expenses and other assets	(707)	(2,658)
(Increase) in income tax receivable/payable, net	(271)	(12,752)
Increase in accounts payable	11,309	579
Decrease in deferred revenue	(7,254)	(2,126)
Increase in accrued Program costs	15,039	18,819
Decrease in other payables and accrued expenses	(5,151)	(4,256)
Net cash provided by operating activities	3,719	34,117
Cash flows from investing activities:
Capital expenditures	(3,230)	(4,155)
Investment		(950)
Acquisition of other intangible assets and businesses	(1,631)	(13,400)
Net cash used in investing activities	(4,861)	(18,505)
Cash flows from financing activities:
Payments under line of credit agreement	(62,125)	(59,025)
Borrowings under line of credit agreement	58,800	45,000
Payments on other long-term liabilities		(26)
Net receipts from the issuance of common stock (sale of stock under ESPP, exercise of stock options, and shares purchased for tax withholding)	1,335	(1,214)
Payment of cash dividends	(1,024)	(724)
Net cash used by financing activities	(3,014)	(15,989)
Net decrease in cash and cash equivalents	(4,156)	(377)
Effect of exchange rate changes on cash and cash equivalents	(82)	105
Cash and cash equivalents at beginning of period	11,337	7,869
Cash and cash equivalents at end of period	$ 7,099	$ 7,597

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2018
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	1. The accompanying unaudited condensed consolidated financial statements of American Vanguard Corporation and Subsidiaries (“AVD”) have been prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and notes required by US GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation, have been included. Operating results for the six months ended June 30, 2018 are not necessarily indicative of the results that may be expected for the year ending December 31, 2018. For further information, refer to the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017.

Revenue Recognition

Revenue Recognition	6 Months Ended
	Jun. 30, 2018
Accounting Policies [Abstract]
Revenue Recognition	2. Revenue Recognition—The Company recognizes revenue from the sale of its products, which include insecticides, herbicides, soil fumigants, and fungicides. The Company sells its products to customers, which include distributors and retailers. In addition, the Company recognizes royalty income from the sale of intellectual property. Based on similar economic and operational characteristics, the Company’s business is aggregated into one reportable segment. Selective enterprise information of sales disaggregated by category and geographic region Three Months Ended June 30, 2018 Six Months Ended June 30, 2018 As reported Without adoption of ASC 606 As reported Without adoption of ASC 606 Net sales: Crop: Insecticides $ 32,665 $ 32,671 $ 73,958 $ 73,988 Herbicides/soil fumigants/fungicides 31,401 31,401 63,586 63,586 Other, including plant growth regulators and distribution 30,377 30,377 48,217 48,217 94,443 94,449 185,761 185,791 Non-crop, including distribution 12,603 12,603 25,393 25,393 Total net sales: $ 107,046 $ 107,052 $ 211,154 $ 211,184 Net sales: US $ 64,363 $ 64,369 $ 134,178 $ 134,208 International 42,683 42,683 76,976 76,976 Total net sales: $ 107,046 $ 107,052 $ 211,154 $ 211,184 Timing of revenue recognition: Goods transferred at a point in time $ 106,886 $ 107,052 $ 210,591 $ 211,184 Goods and services transferred over time 160 — 563 — Total net sales: $ 107,046 $ 107,052 $ 211,154 $ 211,184 In May 2014, Financial Accounting Standards Board, (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers The Company adopted ASC 606 using the modified retrospective method, therefore, the comparative information has not been adjusted and continues to be reported under ASC 605. As part of the Company's adoption of ASC 606, the Company elected to use the following practical expedients (i) not to adjust the promised amount of consideration for the effects of a significant financing component when the Company expects, at contract inception, that the period between the Company's transfer of a promised product or service to a customer and when the customer pays for that product or service will be one year or less (ii) allowing entities the option to treat shipping and handling activities that occur after control of the good transfers to the customer as fulfillment activities. For all of the Company’s sales and distribution channels, revenue is recognized when control of the product is transferred to the customer (i.e., when the Company’s performance obligation is satisfied), which typically occurs at shipment for product sales, but also occurs over time for certain products that are deemed to have no alternative use accompanied by an enforceable right to payment for performance completed to date. For revenue recognized over time, the Company uses an output measure, units produced, to measure progress. From time to time, the Company may offer a Program to eligible customers, in good standing, that provides extended payment terms on a portion of the sales on selected products. The Company analyzes these extended payment Programs in connection with its revenue recognition policy to ensure all revenue recognition criteria are satisfied at the time of sale. Performance Obligations — A performance obligation is a promise in a contract or sales order to transfer a distinct good or service to the customer, and is the unit of account in ASC 606. A transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. Certain of the Company’s sales orders have multiple performance obligations, as the promise to transfer individual goods or services is separately identifiable from other promises in the sales orders. For sales orders with multiple performance obligations, the Company allocates the sales order’s transaction price to each performance obligation based on its relative stand-alone selling price. The stand-alone selling prices are determined based on the prices at which the Company separately sells these products. The Company’s performance obligations are satisfied either at a point in time or over time as work progresses. At June 30, 2018, the Company had $34,616 of remaining performance obligations, which is comprised of deferred revenue and services not yet delivered. The Company expects to recognize approximately all of its remaining performance obligations as revenue in fiscal 2018. Contract Balances — The timing of revenue recognition, billings and cash collections results in deferred revenue in the condensed consolidated balance sheets. The Company sometimes receives payments from its customers in advance of goods and services being provided in return for early cash incentive Programs, resulting in deferred revenues. These liabilities are reported on the condensed consolidated balance sheet at the end of each reporting period. June 30, 2018 December 31, 2017 Total receivables, net $ 106,944 $ 109,605 Contract assets 3,000 — Deferred revenue 7,320 14,574 Revenue recognized for the three and six months ended June 30, 2018, that was included in the deferred revenue balance at the beginning of 2018 were $12,740 and $4,514, respectively. The following table presents the effect of the adoption of ASC 606 on our condensed consolidated balance sheet (unaudited) as of December 31, 2017: As of December 31, 2017 As previously reported Adjustment due to adoption of ASC 606 As adjusted Total assets $ 535,592 $ 3,000 $ 538,592 Deferred income tax liabilities, net 16,284 786 17,070 Retained earnings 238,953 2,214 241,167 In accordance with ASC 606, the disclosure of the impact of adoption to our consolidated statements of operations for the three and six months ended June 30, 2018 were $33 and $57, respectively, reductions in net sales. This revenue will move from being recognized at point in time to be recognized over time. As such, the net sales will be reported as sales in later quarters. In accordance with ASC 606, the disclosure of the impact of adoption to our condensed consolidated balance sheets was as follows: As of June 30, 2018 As reported Balances without adoption of ASC 606 Impact Assets: Contract assets $ 3,000 $ — $ 3,000 Current liabilities: Deferred revenue 7,320 7,263 57 Deferred income tax liabilities 786 — 786 Stockholders' equity: Retained earnings 250,068 247,854 2,214

Property, Plant and Equipment

Property, Plant and Equipment	6 Months Ended
	Jun. 30, 2018
Property Plant And Equipment [Abstract]
Property, Plant and Equipment	3. Property, plant and equipment at June 30, 2018 and December 31, 2017 consists of the following: June 30, 2018 December 31, 2017 Land $ 2,458 $ 2,458 Buildings and improvements 16,787 16,678 Machinery and equipment 106,104 107,722 Office furniture, fixtures and equipment 4,936 4,925 Automotive equipment 1,115 735 Construction in progress 2,912 1,917 Total gross value 134,312 134,435 Less accumulated depreciation (85,913 ) (85,114 ) Total net value $ 48,399 $ 49,321 The Company recognized depreciation expense related to property, plant and equipment of $2,055 and $2,129 for the three months ended June 30, 2018 and 2017, respectively. During the three months ended June 30, 2018 and 2017, the Company eliminated from assets and accumulated depreciation $3,219 and $3,584, respectively, of fully depreciated assets. The Company recognized depreciation expense related to property, plant and equipment of $4,146 and $4,313 for the six months ended June 30, 2018 and 2017, respectively. During the six months ended June 30, 2018 and 2017, the Company eliminated from assets and accumulated depreciation $3,347 and $4,759, respectively, of fully depreciated assets. Substantially all of the Company’s assets are pledged as collateral with its banks.

Inventories

Inventories	6 Months Ended
	Jun. 30, 2018
Inventory Disclosure [Abstract]
Inventories	4. Inventories are stated at the lower of cost or net realizable value. Cost is determined using the first-in, first-out method. The components of inventories consist of the following: June 30, 2018 December 31, 2017 Finished products $ 144,486 $ 107,595 Raw materials 18,694 15,529 $ 163,180 $ 123,124 As of June 30, 2018, we believe our inventories are valued at lower of cost or net realizable value. In July 2015, Financial Accounting Standards Board (“FASB”) issued Accounting Standards Codification (“ASU”) 2015-11, Inventory (Topic 330). Topic 330 currently requires an entity to measure inventory at the lower of cost or market, where market could be replacement cost, net realizable value, or net realizable value less an approximately normal profit margin. This ASU limits the scope to inventory that is measured using first-in, first-out (FIFO) or average cost and requires inventory be measured at the lower of costs or net realizable value. The new standard is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. The Company adopted this new standard effective January 1, 2017. There was no impact on this adoption.

Segment Reporting

Segment Reporting	6 Months Ended
	Jun. 30, 2018
Segment Reporting [Abstract]
Segment Reporting	5. Based on similar economic and operational characteristics, the Company’s business is aggregated into one reportable segment. Selective enterprise information is as follows: Three Months Ended June 30, Six Months Ended June 30, 2018 2017 2018 2017 Net sales: Crop: Insecticides $ 32,665 $ 39,442 $ 73,958 $ 77,384 Herbicides/soil fumigants/fungicides 31,401 16,045 63,586 36,066 Other, including plant growth regulators 30,377 10,096 48,217 13,488 Total crop: 94,443 65,583 185,761 126,938 Non-crop 12,603 12,322 25,393 21,640 Total net sales: $ 107,046 $ 77,905 $ 211,154 $ 148,578 Net sales: US $ 64,363 $ 55,760 $ 134,178 $ 108,004 International 42,683 22,145 76,976 40,574 Total net sales: $ 107,046 $ 77,905 $ 211,154 $ 148,578

Accrued Program Costs

Accrued Program Costs	6 Months Ended
	Jun. 30, 2018
Payables And Accruals [Abstract]
Accrued Program Costs	6. Accrued Program Costs The Company offers various discounts to customers based on the volume purchased within a defined time period, other pricing adjustments, some grower volume incentives or other key performance indicator driven payments made to distributors, retailers or growers, at the end of a growing season. The Company describes these payments as “Programs.” Programs are a critical part of doing business in both the US crop and non-crop chemicals market places. These discount Programs represent variable consideration. In accordance with ASC 606, revenue from sales is recorded at the net sales price, which is the transaction price, and includes estimates of variable consideration. Variable consideration includes amounts expected to be paid to its customers estimated using the expected value method. Each quarter management compares individual sale transactions with Programs to determine what, if any, estimated Program liability has been incurred. Once this initial calculation is made for the specific quarter, sales and marketing management, along with executive and financial management, review the accumulated Program balance and, for volume driven payments, make assessments of whether or not customers are tracking in a manner that indicates that they will meet the requirements set out in agreed upon terms and conditions attached to each Program. Following this assessment, management will make adjustments to the accumulated accrual to properly reflect the Company’s best estimate of the liability at the balance sheet date. The majority of adjustments are made at, or close to, the end of the crop season, at which time customer performance can be more fully assessed. Programs are paid out predominantly on an annual basis, usually in the final quarter of the financial year or the first quarter of the following year. No significant changes in estimates were made during the three and six months ended June 30, 2018 and 2017, respectively.

Cash Dividend

Cash Dividend	6 Months Ended
	Jun. 30, 2018
Cash Dividends [Abstract]
Cash Dividend	7. The Company has declared and paid the following cash dividends in the periods covered by this Form 10-Q: Declaration Date Record Date Distribution Date Dividend Per Share Total Paid June 11, 2018 June 28, 2018 July 12, 2018 $ 0.020 $ 587 March 8, 2018 March 30, 2018 April 13, 2018 $ 0.020 $ 586 December 12, 2017 December 27, 2017 January 10, 2018 $ 0.015 $ 438

Earnings Per Share

Earnings Per Share	6 Months Ended
	Jun. 30, 2018
Earnings Per Share [Abstract]
Earnings Per Share	8. FASB ASC 260 Earnings Per Share (“EPS”) The components of basic and diluted earnings per share were as follows: Three Months Ended June 30, Six Months Ended June 30, 2018 2017 2018 2017 Numerator: Net income attributable to AVD $ 5,599 $ 4,304 $ 10,254 $ 7,756 Denominator: (in thousands) Weighted average shares outstanding-basic 29,330 29,050 29,309 28,999 Dilutive effect of stock options and grants 860 555 804 562 30,190 29,605 30,113 29,561 For the three and six months ended June 30, 2018 and 2017, respectively, no stock options were excluded from the computation of diluted earnings per share.

Indebtedness

Indebtedness	6 Months Ended
	Jun. 30, 2018
Debt Disclosure [Abstract]
Indebtedness	9. The Company has a revolving line of credit that is shown as long-term debt in the condensed consolidated balance sheets at June 30, 2018 and December 31, 2017. The Company has no short-term debt as of June 30, 2018 and December 31, 2017. Debt is summarized in the following table: Long-term indebtedness ($000's) June 30, 2018 December 31, 2017 Revolving line of credit $ 75,100 $ 78,425 Deferred loan fees (842 ) (939 ) Net long-term debt $ 74,258 $ 77,486 As of June 30, 2017, AMVAC Chemical Corporation (“AMVAC”), the Company’s principal operating subsidiary, as borrower, and affiliates (including the Company, AMVAC CV and AMVAC BV), as guarantors and/or borrowers, entered into a Third Amendment to Second Amended and Restated Credit Agreement (the “Credit Agreement”) with a group of commercial lenders led by Bank of the West (AMVAC’s primary bank) as agent, swing line lender and Letter of Credit (“L/C”) issuer. The Credit Agreement is a senior secured lending facility, consisting of a line of credit of up to $250,000, an accordion feature of up to $100,000 and a maturity date of June 30, 2022. The Credit Agreement contains two key financial covenants; namely, borrowers are required to maintain a Consolidated Funded Debt Ratio of no more than 3.25-to-1 and a Consolidated Fixed Charge Covenant Ratio of at least 1.25-to-1. The Company’s borrowing capacity varies with its financial performance, measured in terms of EBITDA as defined in the Credit Agreement, for the trailing twelve month period. Under the Credit Agreement, revolving loans bear interest at a variable rate based, at borrower’s election with proper notice, on either (i) LIBOR plus the “Applicable Rate” which is based upon the Consolidated Funded Debt Ratio (“Eurocurrency Rate Loan”) or (ii) the greater of (x) the Prime Rate, (y) the Federal Funds Rate plus 0.5%, and (z) the Daily One-Month LIBOR Rate plus 1.00%, plus, in the case of (x), (y) or (z) the Applicable Rate (“Alternate Base Rate Loan”). Interest payments for Eurocurrency Rate Loans are payable on the last day of each interest period (either one, two, three or six months, as selected by the borrower) and the maturity date, while interest payments for Alternate Base Rate Loans are payable on the last business day of each month and the maturity date. At June 30, 2018, according to the terms of the Credit Agreement and based on its performance against the most restrictive covenants listed above, the Company had the capacity to increase its borrowings by up to $137,047. This compares to an available borrowing capacity of $143,182, as of June 30, 2017. The level of borrowing capacity is driven by three factors: (1) our financial performance, as measured in EBITDA including both the trailing twelve-month period and proforma basis arising from acquisitions, which have improved, (2) net borrowings, which have increased and (3) the leverage covenant (being the number of times EBITDA the Company may borrow under its credit facility agreement). As of June 30, 2018, the Company was in compliance with all of its debt covenants.

Reclassification

Reclassification	6 Months Ended
	Jun. 30, 2018
Text Block [Abstract]
Reclassification	10. Reclassification—Certain items may have been reclassified in the prior period condensed consolidated financial statements to conform with the June 30, 2018 presentation.

Comprehensive income

Comprehensive income	6 Months Ended
	Jun. 30, 2018
Equity [Abstract]
Comprehensive income	11. Total comprehensive income includes, in addition to net income, changes in equity that are excluded from the condensed consolidated statements of operations and are recorded directly into a separate section of stockholders’ equity on the condensed consolidated balance sheets. For the three and six month periods ended June 30, 2018 and 2017, total comprehensive income consisted of net income attributable to American Vanguard and foreign currency translation adjustments.

Stock Based Compensation

Stock Based Compensation	6 Months Ended
	Jun. 30, 2018
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock Based Compensation	12. Stock Based Compensation—The Company accounts for stock-based awards to employees and directors in accordance with FASB ASC 718, “ Share-Based Payment, The following tables illustrate the Company’s stock based compensation, unamortized stock-based compensation, and remaining weighted average period for the three and six months ended June 30, 2018 and 2017. Stock-Based Compensation for the Three months ended Stock-Based Compensation for the Six months ended Unamortized Stock-Based Compensation Remaining Weighted Average Period (years) June 30, 2018 Restricted Stock $ 988 $ 1,750 $ 7,424 2.2 Performance Based Restricted Stock 481 1,028 3,336 2.2 Total $ 1,469 $ 2,778 $ 10,760 June 30, 2017 Incentive Stock Options $ 86 $ 170 $ 193 0.5 Restricted Stock 777 1,433 5,198 1.4 Performance Based Restricted Stock 321 621 2,157 2.3 Performance Based Options 58 98 117 0.5 Total $ 1,242 $ 2,322 $ 7,665 Stock Options—During the three and six months ended June 30, 2018, the Company did not grant any employees options to acquire shares of common stock. Option activity within each plan is as follows: Incentive Stock Option Plans Weighted Average Price Per Share Exercisable Weighted Average Price Per Share Balance outstanding, December 31, 2017 473,641 $ 9.38 $ 9.38 Options exercised (40,923 ) 11.49 — Balance outstanding, March 31, 2018 432,718 9.19 9.19 Options exercised (38,360 ) 10.02 — Balance outstanding, June 30, 2018 394,358 $ 9.12 $ 9.12 Information relating to stock options at June 30, 2018, summarized by exercise price is as follows: Outstanding Weighted Average Exercisable Weighted Average Exercise Price Per Share Shares Remaining Life (Months) Exercise Price Shares Exercise Price Incentive Stock Option Plan: $7.50 233,545 29 $ 7.5 233,545 $ 7.50 $11.32—$14.49 160,813 76 $ 11.48 160,813 $ 11.48 394,358 $ 9.12 394,358 $ 9.12 The weighted average exercise prices for options granted, and exercisable, and the weighted average remaining contractual life for options outstanding as of June 30, 2018, were as follows: As of June 30, 2018 Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Months) Intrinsic Value (thousands) Incentive Stock Option Plan: Outstanding 394,358 $ 9.12 48 $ 5,452 Expected to Vest 394,358 $ 9.12 48 $ 5,452 Exercisable 394,358 $ 9.12 48 $ 5,452 Common stock grants — Six Months Ended June 30, 2018 Six Months Ended June 30, 2017 Number of Shares Weighted Average Grant Date Fair Value Number of Shares Weighted Average Grant Date Fair Value Nonvested shares at December 31 st 391,753 $ 15.61 324,756 $ 14.75 Granted 254,972 19.97 251,475 16.10 Vested (8,800 ) 12.07 (10,100 ) 12.95 Forfeited (5,265 ) 16.51 (6,544 ) 15.26 Nonvested shares at March 31 st 632,660 17.41 559,587 15.38 Granted 22,308 23.66 38,502 17.08 Vested (20,313 ) 22.82 (188,400 ) 15.22 Forfeited (6,424 ) 17.25 (6,593 ) 15.55 Nonvested shares at June 30th 628,231 $ 17.40 403,096 $ 15.61 Common stock grants — During the six months ended June 30, 2018, the Company issued a total of 277,280 shares of common stock to employees and directors of which 19,313 shares vested immediately, 19,760 shares will vest between a range of 178 days to 1,060 days, and the remaining shares will cliff vest after three years of service. The shares granted in 2018 were average fair valued at $20.27 per share. The fair value was determined by using the publicly traded share price as of the market close on the date of grant. The Company will recognize as expense the fair value of restricted shares over the required service period. During the six months ended June 30, 2017, the Company issued a total of 289,977 shares of common stock to employees and directors of which 24,312 shares vested immediately, 3,900 shares will vest in three equal tranches on the employee’s anniversary, 1,000 shares vested after one year of service, 2,500 shares will cliff vest after two years of service, and the remaining shares will cliff vest after three years of service. The shares granted in 2017 were average fair valued at $16.23 per share. The fair value was determined by using the publicly traded share price as of the market close on the date of grant. The Company will recognize as expense the fair value of restricted shares over the required service period. During the three months ended June 30, 2018 and 2017, the Company recognized stock-based compensation related to restricted shares of $988 and $777, respectively. During the six months ended June 30, 2018 and 2017, the Company recognized stock-based compensation related to restricted shares of $1,750 and $1,433, respectively. As of June 30, 2018, the Company had approximately $7,424 of unamortized stock-based compensation related to unvested restricted shares. This amount will be recognized over the weighted-average period of 2.2 years. This projected expense will change if any restricted shares are granted or cancelled prior to the respective reporting periods or if there are any changes required to be made for estimated forfeitures. Performance Based Shares — Six Months Ended June 30, 2018 Six Months Ended June 30, 2017 Number of Shares Weighted Average Grant Date Fair Value Number of Shares Weighted Average Grant Date Fair Value Nonvested shares at December 31 st 186,057 $ 14.93 119,022 $ 14.18 Granted 122,446 18.79 121,194 15.40 Vested (14,625 ) 11.01 — — Forfeited (1,765 ) 15.40 — — Nonvested shares at March 31 st 292,113 16.74 240,216 14.80 Granted 3,850 22.69 7,400 15.88 Vested — — (48,046 ) 14.92 Forfeited (2,179 ) 17.67 (12,560 ) 12.92 Nonvested shares at June 30th 293,784 $ 16.81 187,010 $ 14.93 Performance Based Shares — During the six months ended June 30, 2018, the Company issued a total of 126,296 performance-based shares to employees. The shares granted have an average fair value of $18.91. The fair value was determined by using the publicly traded share price as of the market close on the date of grant. The Company will recognize as expense, the fair value of the performance based shares over the required service period from grant date. Performance Based Shares — During the six months ended June 30, 2017, the Company issued a total of 128,594 performance-based shares to employees. The shares granted during the six months of 2017 have an average fair value of $15.43. The fair value was determined by using the publicly traded share price as of the market close on the date of grant. The Company will recognize as expense the fair value of the performance based shares over the required service period from grant date. As of June 30, 2018, performance based shares related to EBIT and net sales have an average fair value of $18.88 per share. The fair value was determined by using the publicly traded share price as of the market close on the date of grant. The performance based shares related to the Company’s stock price have an average fair value of $15.85 per share. The fair value was determined by using the Monte Carlo valuation method. For awards with performance conditions, the Company recognizes share-based compensation cost on a straight-line basis for each performance criteria over the implied service period. During the three months ended June 30, 2018 and 2017, the Company recognized stock-based compensation related to performance based shares of $481 and $321, respectively. During the six months ended June 30, 2018 and 2017, the Company recognized stock-based compensation related to performance based shares of $1,028 and $621, respectively. As of June 30, 2018, the Company had approximately $3,336 of unamortized stock-based compensation expense related to unvested performance based shares. This amount will be recognized over the weighted-average period of 2.2 years. This projected expense will change if any performance based shares are granted or cancelled prior to the respective reporting periods or if there are any changes required to be made for estimated forfeitures. Performance Incentive Stock Options—During the six months ended June 30, 2018 and 2017, the Company did not grant any employees performance incentive stock options to acquire shares of common stock. As of June 30, 2018, the Company has concluded that the performance measure based on EBIT and net sales for the performance stock options granted in 2014, when compared to the peer group, was met at 200% of targeted performance and all related additional expenses were recorded as of December 31, 2017. The performance options based on market price was met at 175%, however, the market condition is reflected in the grant date fair value valuation and no additional expenses were recognized as of December 31, 2017. As a result, 77,598 shares were earned through additional vesting based on performance. The balance outstanding as of June 30, 2018 is increased by the additional options issued based on performance. Performance option activity is as follows: Incentive Stock Option Plans Weighted Average Price Per Share Exercisable Weighted Average Price Per Share Balance outstanding, December 31, 2017 and March 31, 2018 81,666 $ 11.49 $ 11.49 Additional vesting based on performance 77,598 11.49 — Options exercised (17,839 ) 11.49 — Balance outstanding, June 30, 2018 141,425 $ 11.49 $ 11.49 Information relating to stock options at June 30, 2018 summarized by exercise price is as follows: Outstanding Weighted Average Exercisable Weighted Average Exercise Price Per Share Shares Remaining Life (Months) Exercise Price Shares Exercise Price Performance Incentive Stock Option Plan: 141,425 78 $ 11.49 141,425 $ 11.49 The weighted average exercise prices for options granted and exercisable and the weighted average remaining contractual life for options outstanding as of June 30, 2018 are as follows: As of June 30, 2018 Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Months) Intrinsic Value (thousands) Performance Incentive Stock Option Plan: Outstanding 141,425 $ 11.49 78 $ 1,621 Expected to Vest 141,425 $ 11.49 78 $ 1,621 Exercisable 141,425 $ 11.49 78 $ 1,621 In March 2016, FASB issued ASU 2016-09, Compensation—Stock Compensation (Topic 718)

Legal Proceedings

Legal Proceedings	6 Months Ended
	Jun. 30, 2018
Commitments And Contingencies Disclosure [Abstract]
Legal Proceedings	13. Legal Proceedings — During the reporting period, there have been no significant developments in material pending or threatened legal proceedings to which the Company is a party, except as described below. Takings Action AMVAC v. EPA FIFRA/RCRA Matter Walker v. AMVAC. Larry L. Walker v. Amvac Chemical Corporation

Recently Issued Accounting Guid

Recently Issued Accounting Guidance	6 Months Ended
	Jun. 30, 2018
Accounting Policies [Abstract]
Recently Issued Accounting Guidance	14. Recently Issued Accounting Guidance — In February 2018, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2018-02, Income Statement-Reporting Comprehensive Income (ASC 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income: In January 2018, the FASB released guidance on the accounting for tax on the global intangible low-taxed income (“GILTI”) provisions of the Tax Cuts and Jobs Act (the “Act”). The GILTI provisions imposed a tax on foreign income in excess of a deemed return on tangible assets of foreign corporations. The Company has considered options regarding the accounting treatment for any potential GILTI inclusions and has elected to treat such inclusions as period costs. In January 2017, the FASB issued ASU 2017-04, Intangibles-Goodwill and Other (ASC 350). In October 2016, FASB issued ASU 2016-16, Income Taxes (ASC 740) In August 2016, FASB issued ASU 2016-15, Statement of Cash Flows (ASC 230) In February 2016, FASB issued ASU 2016-02, Leases The new standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the condensed consolidated financial statements, with certain practical expedients available. We are currently evaluating our operating lease arrangements to determine the impact of this amendment on the condensed consolidated financial statements, We have not determined if the adoption of this standard will materially impact our operating results. The evaluation will include an extensive review of our leases, which are primarily related to our manufacturing sites, regional sales offices, lease vehicles, and office equipment. The ultimate impact will depend on the Company’s lease portfolio at the time the new standard is adopted. The Company will adopt ASU 2016-02 for the year beginning on January 1, 2019. In January 2016, the FASB issued ASU 2016-01, "Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities." The amendment requires (i) equity investments (except those accounted for under the equity method of accounting, or those that result in consolidation of the investee) to be measured at fair value with changes in fair value recognized in net income, (ii) public business entities to use the exit price notion when measuring the fair value of financial instruments for disclosure purposes and (iii) separate presentation of financial assets and financial liabilities by measurement category and form of financial asset (i.e., securities or loans and receivables). This amendment eliminates the requirement for public business entities to disclose the method(s) and significant assumptions used to estimate the fair value that is required to be disclosed for financial instruments measured at amortized cost. This amendment is effective for public companies for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. The Company adopted the provisions of ASU 2016-01 on January 1, 2018 and has elected to measure its cost method investment without a readily determinable fair value at its cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. There were no observable price changes during the three and six months ended June 30, 2018. If there are any observable price changes related to this investment or a similar investment of the same issuer in fiscal years beginning after December 15, 2017, the Company would be required to assess the fair value impact, if any, on each class of stock, and write the individual security interest up or down to its estimated fair value, which could have a significant effect on the Company's financial position and results of operations. The adoption of this standard did not have a material impact on the Company’s condensed consolidated financial statements.

Fair Value of Financial Instrum

Fair Value of Financial Instruments	6 Months Ended
	Jun. 30, 2018
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	15. Fair Value of Financial Instruments— The carrying values of cash, receivables and accounts payable approximate their fair values because of the short maturity of these instruments. The fair value of the Company’s long-term debt payable to the bank is estimated based on the quoted market prices for the same or similar issues or on the current rates offered to the Company for debt of the same remaining maturities. Such fair value approximates the respective carrying values of the Company’s long-term debt payable to bank. During the three and six months ended June 30, 2018, net measurement period adjustments in the amounts of $1,146 and $347, respectively, were made to reduce provisional amounts recorded for deferred consideration in connection with the 2017 AgriCenter acquisition resulting in a reduction to goodwill. As of June 30, 2018, the Company reassessed the fair value of the deferred consideration balances relating to the 2017 AgriCenter and OHP acquisitions, which resulted in a combined reduction of the deferred consideration balances of approximately $1,468 which has been reflected in other income in the condensed consolidated statements of operations for the three months ended June 30, 2018.

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income ("AOCI")	6 Months Ended
	Jun. 30, 2018
Equity [Abstract]
Accumulated Other Comprehensive Income ("AOCI")	16. Accumulated Other Comprehensive Income (“AOCI”) — Total Balance, December 31, 2017 $ (4,507 ) FX translation 672 Balance, March 31, 2018 (3,835 ) FX translation (898 ) Balance, June 30, 2018 $ (4,733 )

Equity Method Investments

Equity Method Investments	6 Months Ended
	Jun. 30, 2018
Equity Method Investments And Joint Ventures [Abstract]
Investments	17. Investments — TyraTech Inc. (“TyraTech”) is a Delaware corporation that specializes in developing, marketing and selling pesticide products containing natural oils. In January 2018, TyraTech finalized a stock repurchase as a result of which the Company’s ownership position in TyraTech increased from approximately 15.11% to approximately 34.38%. The Company utilizes the equity method of accounting with respect to this investment. Accordingly, our net income includes income and losses from equity method investments, which represents our proportionate share of TyraTech’s estimated net losses and impairment charges (if appropriate) for the current accounting period. For the three and six months ended June 30, 2018, the Company recognized a net loss of $347 and $443 as a result of the Company’s ownership position in TyraTech. The Company recognized a loss of $69 and $111 for the three and six months ended June 30, 2017. On June 27, 2017, both Amvac Netherlands BV and Huifeng Agrochemical Company, Ltd (“Huifeng”) made individual capital contributions of $950 to Huifeng Amvac Innovation Co. Ltd (“Hong Kong Joint Venture”). As of June 30, 2018, the Company’s ownership position in the Hong Kong Joint Venture was 50%. The Company utilizes the equity method of accounting with respect to this investment. On July 7, 2017, the Hong Kong Joint Venture purchased the shares of Profeng Australia, Pty Ltd.(“Profeng”), for a total consideration of $1,900. The purchase consists of Profeng Australia, Pty Ltd Trustee and Profeng Australia Unit Trust. Both Trust and Trustee were previously owned by Huifeng via its wholly owned subsidiary Shanghai Biological Focus center. For the three and six months ended June 30, 2018, the Company recognized gains of $46 and losses of $75, respectively, as a result of the Company’s ownership position in the Hong Kong Joint Venture. There were no similar gains or losses recognized in the prior year comparative period. In February 2016, AMVAC Netherlands BV made an investment in Biological Products for Agriculture (“Bi-PA”). Bi-PA develops biological plant protection products that can be used for the control of pests and disease of agricultural crops. As of June 30, 2018, the Company’s ownership position in Bi-PA was 15%. The Company adopted the provisions of ASU 2016-01 on January 1, 2018 and has elected to measure its cost method investment without a readily determinable fair value at its cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. There were no observable price changes in the three and six months ended June 30, 2018. There was no impairment on the investment as of June 30, 2018. The investment is not material and is recorded within other assets on the condensed consolidated balance sheets.

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2018
Income Tax Disclosure [Abstract]
Income Taxes	18. Income Taxes — Income tax expense was $1,748 for the three months ended June 30, 2018, as compared to $1,681 for the comparable period in 2017. The effective tax rate for the quarter was 23.0%, as compared to 26.8% in the same period of the prior year. Income tax expense was $3,440 for the six months ended June 30, 2018, as compared to $3,061 for the six months ended June 30, 2017. The effective tax rate for the six months ended June 30, 2018 and 2017 was 24.4% and 27.5%, respectively. The effective tax rate is based on the projected income for the full year and is subject to ongoing review and adjustment by management. In December 2017, the Tax Cuts and Jobs Act of 2017 (the “Act”) made broad and complex changes to the U.S. tax code, including, but not limited to, (i) reducing the U.S. federal corporate tax rate from 35 percent to 21 percent; and (ii) requiring companies to pay a one-time transition tax on certain unremitted earnings of foreign subsidiaries. The Act also established new tax laws that affect 2018, including, but not limited to: (i) the reduction of the U.S. federal corporate tax rate discussed above; (ii) a general elimination of U.S. federal income taxes on dividends from foreign subsidiaries; (iii) a new provision designed to tax global intangible low-taxed income (“GILTI”); (iv) the repeal of the domestic production activity deductions; (v) limitations on the deductibility of certain executive compensation; and (vi) limitations on the use of foreign tax credits to reduce the U.S. income tax liability. On December 22, 2017, Staff Accounting Bulletin No. 118 (“SAB 118”) was issued to address the application of U.S. GAAP in situations when a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting for certain income tax effects of the Act. For the three and six months ended June 30, 2018, the Company did not obtain additional information affecting the provisional amount initially recorded for the transition tax for 2017. As a result, the Company has not recorded an adjustment to the transition tax. Additional work is ongoing including a more detailed analysis of the Company's deferred tax assets and liabilities and its historical foreign earnings as well as potential correlative adjustments. Any subsequent adjustment to these amounts will be recorded to current tax expense in the quarter of 2018 when the analysis is complete.

Revenue Recognition (Tables)

Revenue Recognition (Tables)	6 Months Ended
	Jun. 30, 2018
Summary of Selective Enterprise Information of Sales Disaggregated By Category and Geographic Region	Selective enterprise information of sales disaggregated by category and geographic region Three Months Ended June 30, 2018 Six Months Ended June 30, 2018 As reported Without adoption of ASC 606 As reported Without adoption of ASC 606 Net sales: Crop: Insecticides $ 32,665 $ 32,671 $ 73,958 $ 73,988 Herbicides/soil fumigants/fungicides 31,401 31,401 63,586 63,586 Other, including plant growth regulators and distribution 30,377 30,377 48,217 48,217 94,443 94,449 185,761 185,791 Non-crop, including distribution 12,603 12,603 25,393 25,393 Total net sales: $ 107,046 $ 107,052 $ 211,154 $ 211,184 Net sales: US $ 64,363 $ 64,369 $ 134,178 $ 134,208 International 42,683 42,683 76,976 76,976 Total net sales: $ 107,046 $ 107,052 $ 211,154 $ 211,184 Timing of revenue recognition: Goods transferred at a point in time $ 106,886 $ 107,052 $ 210,591 $ 211,184 Goods and services transferred over time 160 — 563 — Total net sales: $ 107,046 $ 107,052 $ 211,154 $ 211,184
Summary of Receivables and Contract Liabilities from Contracts with Customers	June 30, 2018 December 31, 2017 Total receivables, net $ 106,944 $ 109,605 Contract assets 3,000 — Deferred revenue 7,320 14,574
Accounting Standards Update 2014-09
Summary of Impact of Adoption to Condensed Consolidated Balance Sheets	The following table presents the effect of the adoption of ASC 606 on our condensed consolidated balance sheet (unaudited) as of December 31, 2017: As of December 31, 2017 As previously reported Adjustment due to adoption of ASC 606 As adjusted Total assets $ 535,592 $ 3,000 $ 538,592 Deferred income tax liabilities, net 16,284 786 17,070 Retained earnings 238,953 2,214 241,167 In accordance with ASC 606, the disclosure of the impact of adoption to our condensed consolidated balance sheets was as follows: As of June 30, 2018 As reported Balances without adoption of ASC 606 Impact Assets: Contract assets $ 3,000 $ — $ 3,000 Current liabilities: Deferred revenue 7,320 7,263 57 Deferred income tax liabilities 786 — 786 Stockholders' equity: Retained earnings 250,068 247,854 2,214

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	6 Months Ended
	Jun. 30, 2018
Property Plant And Equipment [Abstract]
Summary of Property, Plant and Equipment	Property, plant and equipment at June 30, 2018 and December 31, 2017 consists of the following: June 30, 2018 December 31, 2017 Land $ 2,458 $ 2,458 Buildings and improvements 16,787 16,678 Machinery and equipment 106,104 107,722 Office furniture, fixtures and equipment 4,936 4,925 Automotive equipment 1,115 735 Construction in progress 2,912 1,917 Total gross value 134,312 134,435 Less accumulated depreciation (85,913 ) (85,114 ) Total net value $ 48,399 $ 49,321

Inventories (Tables)

Inventories (Tables)	6 Months Ended
	Jun. 30, 2018
Inventory Disclosure [Abstract]
Components of Inventories	The components of inventories consist of the following: June 30, 2018 December 31, 2017 Finished products $ 144,486 $ 107,595 Raw materials 18,694 15,529 $ 163,180 $ 123,124

Segment Reporting (Tables)

Segment Reporting (Tables)	6 Months Ended
	Jun. 30, 2018
Segment Reporting [Abstract]
Summary of Business Sales Segmentation	Selective enterprise information is as follows: Three Months Ended June 30, Six Months Ended June 30, 2018 2017 2018 2017 Net sales: Crop: Insecticides $ 32,665 $ 39,442 $ 73,958 $ 77,384 Herbicides/soil fumigants/fungicides 31,401 16,045 63,586 36,066 Other, including plant growth regulators 30,377 10,096 48,217 13,488 Total crop: 94,443 65,583 185,761 126,938 Non-crop 12,603 12,322 25,393 21,640 Total net sales: $ 107,046 $ 77,905 $ 211,154 $ 148,578 Net sales: US $ 64,363 $ 55,760 $ 134,178 $ 108,004 International 42,683 22,145 76,976 40,574 Total net sales: $ 107,046 $ 77,905 $ 211,154 $ 148,578

Cash Dividend (Tables)

Cash Dividend (Tables)	6 Months Ended
	Jun. 30, 2018
Cash Dividends [Abstract]
Cash Dividend	The Company has declared and paid the following cash dividends in the periods covered by this Form 10-Q: Declaration Date Record Date Distribution Date Dividend Per Share Total Paid June 11, 2018 June 28, 2018 July 12, 2018 $ 0.020 $ 587 March 8, 2018 March 30, 2018 April 13, 2018 $ 0.020 $ 586 December 12, 2017 December 27, 2017 January 10, 2018 $ 0.015 $ 438

Earnings Per Share (Tables)

Earnings Per Share (Tables)	6 Months Ended
	Jun. 30, 2018
Earnings Per Share [Abstract]
Components of Basic and Diluted Earnings Per Share	The components of basic and diluted earnings per share were as follows: Three Months Ended June 30, Six Months Ended June 30, 2018 2017 2018 2017 Numerator: Net income attributable to AVD $ 5,599 $ 4,304 $ 10,254 $ 7,756 Denominator: (in thousands) Weighted average shares outstanding-basic 29,330 29,050 29,309 28,999 Dilutive effect of stock options and grants 860 555 804 562 30,190 29,605 30,113 29,561

Indebtedness (Tables)

Indebtedness (Tables)	6 Months Ended
	Jun. 30, 2018
Debt Disclosure [Abstract]
Summary of Revolving Line of Credit	The Company has a revolving line of credit that is shown as long-term debt in the condensed consolidated balance sheets at June 30, 2018 and December 31, 2017. The Company has no short-term debt as of June 30, 2018 and December 31, 2017. Debt is summarized in the following table: Long-term indebtedness ($000's) June 30, 2018 December 31, 2017 Revolving line of credit $ 75,100 $ 78,425 Deferred loan fees (842 ) (939 ) Net long-term debt $ 74,258 $ 77,486

Stock Based Compensation (Table

Stock Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2018
Stock Based Compensation, Unamortized Stock-Based Compensation and Remaining Weighted Average Period	The following tables illustrate the Company’s stock based compensation, unamortized stock-based compensation, and remaining weighted average period for the three and six months ended June 30, 2018 and 2017. Stock-Based Compensation for the Three months ended Stock-Based Compensation for the Six months ended Unamortized Stock-Based Compensation Remaining Weighted Average Period (years) June 30, 2018 Restricted Stock $ 988 $ 1,750 $ 7,424 2.2 Performance Based Restricted Stock 481 1,028 3,336 2.2 Total $ 1,469 $ 2,778 $ 10,760 June 30, 2017 Incentive Stock Options $ 86 $ 170 $ 193 0.5 Restricted Stock 777 1,433 5,198 1.4 Performance Based Restricted Stock 321 621 2,157 2.3 Performance Based Options 58 98 117 0.5 Total $ 1,242 $ 2,322 $ 7,665
Summary of Option Activity	Option activity within each plan is as follows: Incentive Stock Option Plans Weighted Average Price Per Share Exercisable Weighted Average Price Per Share Balance outstanding, December 31, 2017 473,641 $ 9.38 $ 9.38 Options exercised (40,923 ) 11.49 — Balance outstanding, March 31, 2018 432,718 9.19 9.19 Options exercised (38,360 ) 10.02 — Balance outstanding, June 30, 2018 394,358 $ 9.12 $ 9.12
Summary of Stock Options Summarized by Exercise Price	Information relating to stock options at June 30, 2018, summarized by exercise price is as follows: Outstanding Weighted Average Exercisable Weighted Average Exercise Price Per Share Shares Remaining Life (Months) Exercise Price Shares Exercise Price Incentive Stock Option Plan: $7.50 233,545 29 $ 7.5 233,545 $ 7.50 $11.32—$14.49 160,813 76 $ 11.48 160,813 $ 11.48 394,358 $ 9.12 394,358 $ 9.12
Weighted Average Exercise Prices for Options Granted and Exercisable and Weighted Average Remaining Contractual Life for Options Outstanding	The weighted average exercise prices for options granted, and exercisable, and the weighted average remaining contractual life for options outstanding as of June 30, 2018, were as follows: As of June 30, 2018 Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Months) Intrinsic Value (thousands) Incentive Stock Option Plan: Outstanding 394,358 $ 9.12 48 $ 5,452 Expected to Vest 394,358 $ 9.12 48 $ 5,452 Exercisable 394,358 $ 9.12 48 $ 5,452
Performance Based Stock Options
Summary of Option Activity	Performance option activity is as follows: Incentive Stock Option Plans Weighted Average Price Per Share Exercisable Weighted Average Price Per Share Balance outstanding, December 31, 2017 and March 31, 2018 81,666 $ 11.49 $ 11.49 Additional vesting based on performance 77,598 11.49 — Options exercised (17,839 ) 11.49 — Balance outstanding, June 30, 2018 141,425 $ 11.49 $ 11.49
Performance Incentive Stock Option Plan
Summary of Stock Options Summarized by Exercise Price	Information relating to stock options at June 30, 2018 summarized by exercise price is as follows: Outstanding Weighted Average Exercisable Weighted Average Exercise Price Per Share Shares Remaining Life (Months) Exercise Price Shares Exercise Price Performance Incentive Stock Option Plan: 141,425 78 $ 11.49 141,425 $ 11.49
Weighted Average Exercise Prices for Options Granted and Exercisable and Weighted Average Remaining Contractual Life for Options Outstanding	The weighted average exercise prices for options granted and exercisable and the weighted average remaining contractual life for options outstanding as of June 30, 2018 are as follows: As of June 30, 2018 Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Months) Intrinsic Value (thousands) Performance Incentive Stock Option Plan: Outstanding 141,425 $ 11.49 78 $ 1,621 Expected to Vest 141,425 $ 11.49 78 $ 1,621 Exercisable 141,425 $ 11.49 78 $ 1,621
Common Stock Grants
Summary of Non-Vested Shares	Common stock grants — Six Months Ended June 30, 2018 Six Months Ended June 30, 2017 Number of Shares Weighted Average Grant Date Fair Value Number of Shares Weighted Average Grant Date Fair Value Nonvested shares at December 31 st 391,753 $ 15.61 324,756 $ 14.75 Granted 254,972 19.97 251,475 16.10 Vested (8,800 ) 12.07 (10,100 ) 12.95 Forfeited (5,265 ) 16.51 (6,544 ) 15.26 Nonvested shares at March 31 st 632,660 17.41 559,587 15.38 Granted 22,308 23.66 38,502 17.08 Vested (20,313 ) 22.82 (188,400 ) 15.22 Forfeited (6,424 ) 17.25 (6,593 ) 15.55 Nonvested shares at June 30th 628,231 $ 17.40 403,096 $ 15.61
Performance Based Restricted Shares
Summary of Non-Vested Shares	Performance Based Shares — Six Months Ended June 30, 2018 Six Months Ended June 30, 2017 Number of Shares Weighted Average Grant Date Fair Value Number of Shares Weighted Average Grant Date Fair Value Nonvested shares at December 31 st 186,057 $ 14.93 119,022 $ 14.18 Granted 122,446 18.79 121,194 15.40 Vested (14,625 ) 11.01 — — Forfeited (1,765 ) 15.40 — — Nonvested shares at March 31 st 292,113 16.74 240,216 14.80 Granted 3,850 22.69 7,400 15.88 Vested — — (48,046 ) 14.92 Forfeited (2,179 ) 17.67 (12,560 ) 12.92 Nonvested shares at June 30th 293,784 $ 16.81 187,010 $ 14.93

Accumulated Other Comprehensi35

Accumulated Other Comprehensive Income ("AOCI") (Tables)	6 Months Ended
	Jun. 30, 2018
Equity [Abstract]
Beginning Balance, Annual Activity and Ending Balance of Accumulated Other Comprehensive Loss	The following table lists the beginning balance, annual activity and ending balance of accumulated other comprehensive loss, which consists of foreign currency translation adjustments: Total Balance, December 31, 2017 $ (4,507 ) FX translation 672 Balance, March 31, 2018 (3,835 ) FX translation (898 ) Balance, June 30, 2018 $ (4,733 )

Revenue Recognition - Additiona

Revenue Recognition - Additional Information (Detail) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018USD ($)	Jun. 30, 2017USD ($)	Jun. 30, 2018USD ($)Segment	Jun. 30, 2017USD ($)
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Number of reportable segments | Segment			1
Remaining performance obligations	$ 34,616		$ 34,616
Revenue recognized	12,740		4,514
Net sales	107,046	$ 77,905	211,154	$ 148,578
Accounting Standards Update 2014-09
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Net sales	107,046		211,154
Accounting Standards Update 2014-09 | Adjustment Due to Adoption of Topic 606
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Net sales	$ (33)		$ (57)

Revenue Recognition - Summary o

Revenue Recognition - Summary of Selective Enterprise Information of Sales Disaggregated By Category and Geographic Region (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Net sales
Net sales	$ 107,046	$ 77,905	$ 211,154	$ 148,578
Insecticides
Net sales
Net sales	32,665	39,442	73,958	77,384
Herbicides/Soil Fumigants/Fungicides
Net sales
Net sales	31,401	16,045	63,586	36,066
Crop
Net sales
Net sales	94,443	65,583	185,761	126,938
US
Net sales
Net sales	64,363	55,760	134,178	108,004
International
Net sales
Net sales	42,683	$ 22,145	76,976	$ 40,574
Accounting Standards Update 2014-09
Net sales
Net sales	107,046		211,154
Accounting Standards Update 2014-09 | Insecticides
Net sales
Net sales	32,665		73,958
Accounting Standards Update 2014-09 | Herbicides/Soil Fumigants/Fungicides
Net sales
Net sales	31,401		63,586
Accounting Standards Update 2014-09 | Other, Including Plant Growth Regulators and Distribution
Net sales
Net sales	30,377		48,217
Accounting Standards Update 2014-09 | Crop
Net sales
Net sales	94,443		185,761
Accounting Standards Update 2014-09 | Non Crop Including Distribution
Net sales
Net sales	12,603		25,393
Accounting Standards Update 2014-09 | US
Net sales
Net sales	64,363		134,178
Accounting Standards Update 2014-09 | International
Net sales
Net sales	42,683		76,976
Accounting Standards Update 2014-09 | Goods Transferred At A Point In Time
Net sales
Net sales	106,886		210,591
Accounting Standards Update 2014-09 | Goods And Services Transferred Over Time
Net sales
Net sales	160		563
Accounting Standards Update 2014-09 | Balances without adoption of Topic 606
Net sales
Net sales	107,052		211,184
Accounting Standards Update 2014-09 | Balances without adoption of Topic 606 | Insecticides
Net sales
Net sales	32,671		73,988
Accounting Standards Update 2014-09 | Balances without adoption of Topic 606 | Herbicides/Soil Fumigants/Fungicides
Net sales
Net sales	31,401		63,586
Accounting Standards Update 2014-09 | Balances without adoption of Topic 606 | Other, Including Plant Growth Regulators and Distribution
Net sales
Net sales	30,377		48,217
Accounting Standards Update 2014-09 | Balances without adoption of Topic 606 | Crop
Net sales
Net sales	94,449		185,791
Accounting Standards Update 2014-09 | Balances without adoption of Topic 606 | Non Crop Including Distribution
Net sales
Net sales	12,603		25,393
Accounting Standards Update 2014-09 | Balances without adoption of Topic 606 | US
Net sales
Net sales	64,369		134,208
Accounting Standards Update 2014-09 | Balances without adoption of Topic 606 | International
Net sales
Net sales	42,683		76,976
Accounting Standards Update 2014-09 | Balances without adoption of Topic 606 | Goods Transferred At A Point In Time
Net sales
Net sales	$ 107,052		$ 211,184

Revenue Recognition - Summary38

Revenue Recognition - Summary of Receivables and Contract Liabilities from Contracts with Customers (Detail) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Contract With Customer Liability [Abstract]
Total receivables, net	$ 106,944	$ 109,605
Contract assets	3,000
Deferred revenue	$ 7,320	$ 14,574

Revenue Recognition - Summary39

Revenue Recognition - Summary of Adoption of ASU 2014-09 on Condensed Consolidated Balance Sheets (Detail) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Total assets	$ 562,014	$ 535,592
Deferred income tax liabilities, net	17,224	16,284
Retained earnings	250,068	238,953
Accounting Standards Update 2014-09
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Retained earnings	250,068
Adjustment Due to Adoption of Topic 606 | Accounting Standards Update 2014-09
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Total assets		3,000
Deferred income tax liabilities, net		786
Retained earnings	2,214	2,214
Balances without adoption of Topic 606 | Accounting Standards Update 2014-09
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Total assets		538,592
Deferred income tax liabilities, net		17,070
Retained earnings	$ 247,854	$ 241,167

Revenue Recognition - Summary40

Revenue Recognition - Summary of Impact of Adoption to Condensed Consolidated Balance Sheets (Detail) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Assets:
Contract assets	$ 3,000
Current liabilities:
Deferred revenue	7,320	$ 14,574
Stockholders' equity:
Retained earnings	250,068	238,953
Accounting Standards Update 2014-09
Assets:
Contract assets	3,000
Current liabilities:
Deferred revenue	7,320
Deferred income tax liabilities	786
Stockholders' equity:
Retained earnings	250,068
Accounting Standards Update 2014-09 | Balances without adoption of Topic 606
Current liabilities:
Deferred revenue	7,263
Stockholders' equity:
Retained earnings	247,854	241,167
Accounting Standards Update 2014-09 | Adjustment Due to Adoption of Topic 606
Assets:
Contract assets	3,000
Current liabilities:
Deferred revenue	57
Deferred income tax liabilities	786
Stockholders' equity:
Retained earnings	$ 2,214	$ 2,214

Summary of Property, Plant and

Summary of Property, Plant and Equipment (Detail) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Property, Plant and Equipment [Line Items]
Total gross value	$ 134,312	$ 134,435
Less accumulated depreciation	(85,913)	(85,114)
Total net value	48,399	49,321
Land
Property, Plant and Equipment [Line Items]
Total gross value	2,458	2,458
Buildings and improvements
Property, Plant and Equipment [Line Items]
Total gross value	16,787	16,678
Machinery and equipment
Property, Plant and Equipment [Line Items]
Total gross value	106,104	107,722
Office furniture, fixtures and equipment
Property, Plant and Equipment [Line Items]
Total gross value	4,936	4,925
Automotive equipment
Property, Plant and Equipment [Line Items]
Total gross value	1,115	735
Construction in progress
Property, Plant and Equipment [Line Items]
Total gross value	$ 2,912	$ 1,917

Property, Plant And Equipment -

Property, Plant And Equipment - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Property Plant And Equipment [Abstract]
Depreciation expense related to property, plant and equipment	$ 2,055	$ 2,129	$ 4,146	$ 4,313
Elimination of Assets and Accumulated depreciation	$ 3,219	$ 3,584	$ 3,347	$ 4,759

Components of Inventories (Deta

Components of Inventories (Detail) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Inventory Disclosure [Abstract]
Finished products	$ 144,486	$ 107,595
Raw materials	18,694	15,529
Total Inventories	$ 163,180	$ 123,124

Segment Reporting - Additional

Segment Reporting - Additional Information (Detail)	6 Months Ended
	Jun. 30, 2018Segment
Segment Reporting [Abstract]
Number of reportable business segments	1

Summary of Business Sales by Pr

Summary of Business Sales by Product and Geographic Location (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Net sales
Net sales	$ 107,046	$ 77,905	$ 211,154	$ 148,578
Insecticides
Net sales
Net sales	32,665	39,442	73,958	77,384
Herbicides/Soil Fumigants/Fungicides
Net sales
Net sales	31,401	16,045	63,586	36,066
Other, Including Plant Growth Regulators
Net sales
Net sales	30,377	10,096	48,217	13,488
Crop
Net sales
Net sales	94,443	65,583	185,761	126,938
Non-Crop
Net sales
Net sales	12,603	12,322	25,393	21,640
US
Net sales
Net sales	64,363	55,760	134,178	108,004
International
Net sales
Net sales	$ 42,683	$ 22,145	$ 76,976	$ 40,574

Cash Dividend (Detail)

Cash Dividend (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		12 Months Ended
	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017
Supplemental Cash Flow Elements [Abstract]
Cash dividend declaration date	Jun. 11, 2018	Mar. 8, 2018	Dec. 12, 2017
Cash dividend record date	Jun. 28, 2018	Mar. 30, 2018	Dec. 27, 2017
Cash dividend distributed date	Jul. 12, 2018	Apr. 13, 2018	Jan. 10, 2018
Cash dividend per share	$ 0.020	$ 0.020	$ 0.015
Cash dividend paid	$ 587	$ 586	$ 438

Components of Basic and Diluted

Components of Basic and Diluted Earnings Per Share (Detail) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Numerator:
Net income attributable to AVD	$ 5,599	$ 4,304	$ 10,254	$ 7,756
Denominator:
Weighted average shares outstanding—basic	29,330	29,050	29,309	28,999
Dilutive effect of stock options and grants	860	555	804	562
Weighted average shares outstanding-assuming dilution	30,190	29,605	30,113	29,561

Earnings Per Share - Additional

Earnings Per Share - Additional Information (Detail) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Earnings Per Share [Abstract]
Stock options excluded from computation of diluted earning per share	0	0	0	0

Indebtedness - Additional Infor

Indebtedness - Additional Information (Detail) - USD ($)	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2018	Dec. 31, 2017
Debt Instrument [Line Items]
Short term debt		$ 0	$ 0
Senior secured credit facility, maturity date	Jun. 30, 2022
Revolving Credit Facility
Debt Instrument [Line Items]
Available borrowings capacity under credit agreement	$ 143,182,000
Maximum
Debt Instrument [Line Items]
Available borrowings capacity under credit agreement	$ 250,000,000
Consolidated funded debt ratio	325.00%
Maximum | Revolving Credit Facility
Debt Instrument [Line Items]
Capacity to increase borrowings under credit agreement		$ 137,047,000
Maximum | Term Loan
Debt Instrument [Line Items]
Accordion feature	$ 100,000,000
Minimum
Debt Instrument [Line Items]
Consolidated fixed charge covenant ratio	125.00%

Summary of Revolving Line of Cr

Summary of Revolving Line of Credit (Detail) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Debt Disclosure [Abstract]
Revolving line of credit	$ 75,100	$ 78,425
Deferred loan fees	(842)	(939)
Net long-term debt	$ 74,258	$ 77,486

Unamortized Stock-Based Compens

Unamortized Stock-Based Compensation Expenses (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-Based Compensation	$ 1,469	$ 1,242	$ 2,778	$ 2,322
Unamortized Stock-Based Compensation	10,760	7,665	10,760	7,665
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-Based Compensation	$ 988	$ 777	$ 1,750	$ 1,433
Remaining Weighted Average Period (years)	2 years 2 months 12 days	1 year 4 months 24 days	2 years 2 months 12 days	1 year 4 months 24 days
Unamortized Stock-Based Compensation	$ 7,424	$ 5,198	$ 7,424	$ 5,198
Performance Based Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-Based Compensation	$ 481	$ 321	$ 1,028	$ 621
Remaining Weighted Average Period (years)	2 years 2 months 12 days	2 years 3 months 18 days	2 years 2 months 12 days	2 years 3 months 18 days
Unamortized Stock-Based Compensation	$ 3,336	$ 2,157	$ 3,336	$ 2,157
Incentive Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-Based Compensation		$ 86		$ 170
Remaining Weighted Average Period (years)		6 months		6 months
Unamortized Stock-Based Compensation		$ 193		$ 193
Performance Based Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-Based Compensation		$ 58		$ 98
Remaining Weighted Average Period (years)		6 months		6 months
Unamortized Stock-Based Compensation		$ 117		$ 117

Stock Based Compensation - Addi

Stock Based Compensation - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	Jun. 08, 2016	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2017	Mar. 31, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employees options granted		0				0
Number of shares vested						19,313	24,312
Number of shares expected to vest		19,760		3,900		19,760	3,900
Stock-based compensation		$ 1,469		$ 1,242		$ 2,778	$ 2,322
Performance Based Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares expected to vest		77,598				77,598		77,598
Number of Shares, Granted						0	0
Targeted performance percentage								200.00%
Target performance percentage to meet performance measure based on net sales								175.00%
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares vested		20,313	8,800	188,400	10,100
Weighted Average Grant-Date Fair Value, Granted		$ 23.66	$ 19.97	$ 17.08	$ 16.10
Stock-based compensation		$ 988		$ 777		$ 1,750	$ 1,433
Unamortized Stock-Based Compensation		$ 7,424		$ 5,198		$ 7,424	$ 5,198
Remaining Weighted Average Period (years)		2 years 2 months 12 days		1 year 4 months 24 days		2 years 2 months 12 days	1 year 4 months 24 days
Number of Shares, Granted		22,308	254,972	38,502	251,475
Unvested Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unamortized Stock-Based Compensation		$ 7,424				$ 7,424
Remaining Weighted Average Period (years)						2 years 2 months 12 days
Performance Based Restricted Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares vested			14,625	48,046
Weighted Average Grant-Date Fair Value, Granted	$ 15.43	$ 22.69	$ 18.79	$ 15.88	$ 15.40	$ 18.91
Stock-based compensation		$ 481		$ 321		$ 1,028	$ 621
Unamortized Stock-Based Compensation		$ 3,336		$ 2,157		$ 3,336	$ 2,157
Remaining Weighted Average Period (years)		2 years 2 months 12 days		2 years 3 months 18 days		2 years 2 months 12 days	2 years 3 months 18 days
Number of Shares, Granted		3,850	122,446	7,400	121,194	126,296	128,594
Targeted performance percentage		200.00%		200.00%		200.00%	200.00%
Unvested Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unamortized Stock-Based Compensation		$ 3,336				$ 3,336
Remaining Weighted Average Period (years)						2 years 2 months 12 days
Common Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares issued by equity investee						277,280	289,977
Weighted Average Grant-Date Fair Value, Granted						$ 20.27	$ 16.23
Share-based Compensation Award, Tranche One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares expected to vest				1,000			1,000
Number of days of service before cliff vesting							1 year
Share-based Compensation Award, Tranche One | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of days of service before cliff vesting						178 days
Share-based Compensation Award, Tranche One | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of days of service before cliff vesting						1060 days
After Three Years
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of days of service before cliff vesting						3 years	3 years
After Two Year
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares expected to vest				2,500			2,500
Number of days of service before cliff vesting							2 years
Vested on March 9, 2021 | Performance Based Restricted Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Cliff vesting date						Mar. 9, 2021	Feb. 8, 2020
Performance based stock options based upon financial performance of earnings before interest and tax ("EBIT") and net sales goal for the period commencing January 1, 2017 through December 31, 2019 | Performance Based Restricted Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of shares vesting based on Performance						80.00%
Earnings before income taxes goal weight, percentage						50.00%
Net sales goal weight, percentage						30.00%
Performance Based Shares Based Upon AVD Stock Price Appreciation Over the Course of the Period Commencing January 1, 2017 through December 31, 2019 | Performance Based Restricted Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Earnings before income taxes goal weight, percentage						20.00%
Performance based stock options based upon financial performance of earnings before interest and tax ("EBIT") and net sales goal for the period commencing January 1, 2016 and ending December 31, 2018 | Performance Based Restricted Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of shares vesting based on Performance							80.00%
Earnings before income taxes goal weight, percentage							50.00%
Net sales goal weight, percentage							30.00%
Performance Based Shares Based Upon AVD Stock Price Appreciation Over the Course of the Period Commencing January 1, 2016 and ending December 31, 2018 | Performance Based Restricted Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Earnings before income taxes goal weight, percentage							20.00%
Performance Based Shares Related to Net Income Weighted at 50%, Net Sales Weighted at 30%, Commencing January 1, 2017 and Ending December 31, 2019 | Performance Based Restricted Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Grant-Date Fair Value, Granted						$ 18.88
Remaining 20% of Performance Based Shares are Based Upon AVD Stock Price Appreciation for the Period Commencing January 1, 2017 and Ending December 31, 2019 | Performance Based Restricted Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Grant-Date Fair Value, Granted						$ 15.85

Summary of Option Activity (Det

Summary of Option Activity (Detail) - Incentive Stock Options - $ / shares	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Incentive Stock Option Plans, Beginning balance	432,718	473,641	473,641
Incentive Stock Option Plans, Option exercised	(38,360)	(40,923)
Incentive Stock Option Plans, Ending balance	394,358	432,718	394,358
Weighted Average Price Per Share, Beginning balance	$ 9.19	$ 9.38	$ 9.38
Weighted Average Price Per Share, Option exercised	10.02	11.49
Weighted Average Price Per Share, Ending balance	9.12	9.19	9.12
Exercisable Weighted Average Price Per Share, Beginning balance	9.19	9.38	9.38
Exercisable Weighted Average Price Per Share, Ending balance	$ 9.12	$ 9.19	$ 9.12

Summary of Stock Options Summar

Summary of Stock Options Summarized by Exercise Price (Detail) - Incentive Stock Options - $ / shares	6 Months Ended
	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding Weighted Average, Shares	394,358
Outstanding Weighted Average, Exercise Price	$ 9.12	$ 9.19	$ 9.38
Exercisable Weighted Average, Shares	394,358
Exercisable Weighted Average, Exercise Price	$ 9.12	$ 9.19	$ 9.38
Range One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Per Share, Lower Range	$ 7.50
Outstanding Weighted Average, Shares	233,545
Outstanding Weighted Average, Remaining Life (Months)	29 months
Outstanding Weighted Average, Exercise Price	$ 7.5
Exercisable Weighted Average, Shares	233,545
Exercisable Weighted Average, Exercise Price	$ 7.50
Range Two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Per Share, Lower Range	11.32
Exercise Price Per Share, Upper Range	$ 14.49
Outstanding Weighted Average, Shares	160,813
Outstanding Weighted Average, Remaining Life (Months)	76 months
Outstanding Weighted Average, Exercise Price	$ 11.48
Exercisable Weighted Average, Shares	160,813
Exercisable Weighted Average, Exercise Price	$ 11.48

Weighted Average Exercise Price

Weighted Average Exercise Prices for Options Granted and Exercisable and Weighted Average Remaining Contractual Life for Options Outstanding (Detail) - USD ($) $ / shares in Units, $ in Thousands	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Expected to Vest	19,760	3,900
Incentive Stock Option Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Outstanding	394,358
Number of Shares, Expected to Vest	394,358
Number of Shares, Exercisable	394,358
Weighted Average Exercise Price, Outstanding	$ 9.12
Weighted Average Exercise Price, Expected to Vest	9.12
Weighted Average Exercisable, Exercise Price	$ 9.12
Weighted Average Remaining Life, Outstanding	48 months
Weighted Average Remaining Contractual Life, Expected to Vest	48 months
Weighted Average Remaining Contractual Life, Exercisable	48 months
Intrinsic Value, Outstanding	$ 5,452
Intrinsic Value, Expected to Vest	5,452
Intrinsic Value, Exercisable	$ 5,452

Summary of Non-Vested Shares (D

Summary of Non-Vested Shares (Detail) - $ / shares	3 Months Ended				6 Months Ended
	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2017	Mar. 31, 2017	Jun. 30, 2018	Jun. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Vested					(19,313)	(24,312)
Common Stock Grants
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Beginning balance	632,660	391,753	559,587	324,756	391,753	324,756
Number of Shares, Granted	22,308	254,972	38,502	251,475
Number of Shares, Vested	(20,313)	(8,800)	(188,400)	(10,100)
Number of Shares, Forfeited	(6,424)	(5,265)	(6,593)	(6,544)
Number of Shares, Ending Balance	628,231	632,660	403,096	559,587	628,231	403,096
Weighted Average Grant-Date Fair Value, Beginning balance	$ 17.41	$ 15.61	$ 15.38	$ 14.75	$ 15.61	$ 14.75
Weighted Average Grant-Date Fair Value, Granted	23.66	19.97	17.08	16.10
Weighted Average Grant-Date Fair Value, Vested	22.82	12.07	15.22	12.95
Weighted Average Grant-Date Fair Value, Forfeited	17.25	16.51	15.55	15.26
Weighted Average Grant-Date Fair Value, Ending balance	$ 17.40	$ 17.41	$ 15.61	$ 15.38	$ 17.40	$ 15.61

Status Summary of Non-Vested Sh

Status Summary of Non-Vested Shares (Detail) - $ / shares	Jun. 08, 2016	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2017	Mar. 31, 2017	Jun. 30, 2018	Jun. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Vested						(19,313)	(24,312)
Performance Based Restricted Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Beginning balance		292,113	186,057	240,216	119,022	186,057	119,022
Number of Shares, Granted		3,850	122,446	7,400	121,194	126,296	128,594
Number of Shares, Vested			(14,625)	(48,046)
Number of Shares, Forfeited		(2,179)	(1,765)	(12,560)
Number of Shares, Ending Balance		293,784	292,113	187,010	240,216	293,784	187,010
Weighted Average Grant-Date Fair Value, Beginning balance		$ 16.74	$ 14.93	$ 14.80	$ 14.18	$ 14.93	$ 14.18
Weighted Average Grant-Date Fair Value, Granted	$ 15.43	22.69	18.79	15.88	15.40	18.91
Weighted Average Grant-Date Fair Value, Vested			11.01	14.92
Weighted Average Grant-Date Fair Value, Forfeited		17.67	15.40	12.92
Weighted Average Grant-Date Fair Value, Ending balance		$ 16.81	$ 16.74	$ 14.93	$ 14.80	$ 16.81	$ 14.93

Summary of Performance option a

Summary of Performance option activity (Detail) - $ / shares	6 Months Ended
	Jun. 30, 2018	Dec. 31, 2017	Jun. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Incentive Stock Options Plans, Additional vesting based on performance	19,760		3,900
Performance Based Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Incentive Stock Option Plans, Beginning balance	81,666
Incentive Stock Options Plans, Additional vesting based on performance	77,598	77,598
Incentive Stock Options Plans, Options exercised	(17,839)
Incentive Stock Option Plans, Ending balance	141,425
Weighted Average Price Per Share, Beginning balance	$ 11.49
Weighted Average Price Per Share, Additional vesting based on performance	11.49
Weighted Average Price Per Share, Options exercised	11.49
Weighted Average Price Per Share, Ending balance	11.49
Exercisable Weighted Average Price Per Share, Beginning balance	11.49
Exercisable Weighted Average Price Per Share, Ending balance	$ 11.49

Performance Options Summarized

Performance Options Summarized by Exercise Price (Detail) - Performance Incentive Stock Option Plan	6 Months Ended
	Jun. 30, 2018$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding Weighted Average, Shares | shares	141,425
Outstanding Weighted Average, Remaining Life (Months)	78 months
Outstanding Weighted Average, Exercise Price | $ / shares	$ 11.49
Exercisable Weighted Average, Shares | shares	141,425
Exercisable Weighted Average, Exercise Price | $ / shares	$ 11.49

Performance Option Weighted Ave

Performance Option Weighted Average Exercise Prices for Options Granted and Exercisable and Weighted Average Remaining Contractual Life for Options Outstanding (Detail) - USD ($) $ / shares in Units, $ in Thousands	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Expected to Vest	19,760	3,900
Performance Incentive Stock Option Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Outstanding	141,425
Number of Shares, Expected to Vest	141,425
Number of Shares, Exercisable	141,425
Weighted Average Exercise Price, Outstanding	$ 11.49
Weighted Average Exercise Price, Expected to Vest	11.49
Weighted Average Exercisable, Exercise Price	$ 11.49
Weighted Average Remaining Life, Outstanding	78 months
Weighted Average Remaining Contractual Life, Expected to Vest	78 months
Weighted Average Remaining Contractual Life, Exercisable	78 months
Intrinsic Value, Outstanding	$ 1,621
Intrinsic Value, Expected to Vest	1,621
Intrinsic Value, Exercisable	$ 1,621

Legal Proceedings - Additional

Legal Proceedings - Additional Information (Detail)	Nov. 10, 2016USD ($)	Jun. 14, 2016USD ($)	Jun. 30, 2018Witness
USEPA
Loss Contingencies [Line Items]
Loss contingency damages sought, value		$ 25,000,000
Loss contingency damages awarded, value		$ 0
AMVAC v. EPA FIFRA/RCRA Matter
Loss Contingencies [Line Items]
Legal costs and fees	$ 2,000,000
Number of corporate witnesses completed the interview | Witness			4

Recently Issued Accounting Gu62

Recently Issued Accounting Guidance - Additional Information (Detail) $ in Thousands	Jan. 01, 2018USD ($)
Adopted ASU 2016-16
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Reduction to retained earnings	$ (180)

Fair Value of Financial Instr63

Fair Value of Financial Instruments - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2018
Agricenter
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Deferred consideration adjustment	$ 1,146	$ 347
AgriCenter And OHP
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Deferred consideration adjustment	$ 1,468

Beginning Balance, Annual Activ

Beginning Balance, Annual Activity and Ending Balance of Accumulated Other Comprehensive Loss (Detail) - USD ($) $ in Thousands	3 Months Ended			6 Months Ended
	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	$ 314,158	$ 305,314		$ 305,314
Foreign currency translation adjustment	(898)	672	$ 280	(226)	$ 1,037
Balance	320,231	314,158		320,231
Accumulated Foreign Currency Adjustment Attributable to Parent
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	(3,835)	(4,507)		(4,507)
Foreign currency translation adjustment	(898)	672
Balance	$ (4,733)	$ (3,835)		$ (4,733)

Investments - Additional Inform

Investments - Additional Information (Detail) - USD ($) $ in Thousands	Jul. 07, 2017	Jun. 27, 2017	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Jan. 31, 2018	Dec. 31, 2017
Equity Method Investments [Line Items]
Gain (loss) from equity method investment					$ (518)	$ (111)
Investment		$ 950				950
Bi-PA
Equity Method Investments [Line Items]
Equity investment ownership position			15.00%		15.00%
Cost-method Investments, Other than Temporary Impairment					$ 0
Profeng Australia, Pty Ltd
Equity Method Investments [Line Items]
Joint venture, consideration	$ 1,900
TyraTech Inc.
Equity Method Investments [Line Items]
Equity investment ownership position							34.38%	15.11%
Gain (loss) from equity method investment			$ (347)	$ (69)	$ (443)	(111)
Hong Kong JV
Equity Method Investments [Line Items]
Equity investment ownership position			50.00%		50.00%
Gain (loss) from equity method investment			$ 46	$ 0	$ (75)	$ 0

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Income tax expense	$ 1,748	$ 1,681	$ 3,440	$ 3,061
Effective tax rate	23.00%	26.80%	24.40%	27.50%
Federal income tax rate			21.00%		35.00%